FDA-approved spinal implant for chronic low back pain treatment
Mainstay Medical manufactures ReActiv8, an FDA-cleared restorative implant for mechanical chronic low back pain. The company is heavily sales-focused—24 of 36 active roles target sales and business development—while the tech stack (Salesforce, Power BI, Power Automate) reflects a Microsoft-centric, enterprise-sales operating model. Active projects cluster around clinical education and territory expansion, with pain points centered on adoption barriers and reimbursement complexity, signaling a sales cycle constrained by clinical validation and payer acceptance rather than product engineering.
Mainstay Medical develops and commercializes ReActiv8, a spinal implant indicated for chronic mechanical low back pain. The company was incorporated in Dublin, Ireland in 2008 and is now headquartered in San Diego, California, with subsidiaries across Ireland, the United States, Australia, Germany, and the Netherlands. With 51–200 employees, the organization operates a geographically distributed sales and clinical support infrastructure. The business model centers on direct clinical education, territory-based sales execution, and reimbursement navigation—core to adoption in orthopedic and spine markets.
Mainstay Medical actively hires in the United States, Canada, India, Germany, and Peru. The majority of open roles target sales and business development functions.
The primary stack is Microsoft-centric: Office, Salesforce, Power BI, SharePoint, Microsoft 365, Teams, Intune, and Power Automate. React is in active adoption.
Current projects focus on clinical education (awareness campaigns, clinical champions programs), territory business planning, and customized educational content to drive therapy adoption and sales growth.
Other companies in the same industry, closest in size